Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000724129 | SCV000230015 | likely pathogenic | not provided | 2014-07-16 | criteria provided, single submitter | clinical testing | |
Counsyl | RCV000021949 | SCV000790182 | likely pathogenic | Biotinidase deficiency | 2017-03-17 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000021949 | SCV004037699 | pathogenic | Biotinidase deficiency | 2023-08-29 | criteria provided, single submitter | clinical testing | Variant summary: BTD c.569A>G (p.Tyr190Cys) results in a non-conservative amino acid change located in the Carbon-nitrogen hydrolase domain (IPR003010) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 251486 control chromosomes (gnomAD). c.569A>G has been reported in the literature in multiple compound heterozygous and homozygous individuals affected with Biotinidase Deficiency (e.g., Pomponio_1997, Norrgard_1999, Sarafoglou_2009, Gannavarapu_2015). These data indicate that the variant is very likely to be associated with disease. The following publications have been ascertained in the context of this evaluation (PMID: 26361991, 10400129, 9396567, 19757147). One submitter has reported clinical-significance assessments for this variant to ClinVar after 2014 and has classified the variant as pathogenic/likely pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. |
Baylor Genetics | RCV000021949 | SCV004211454 | pathogenic | Biotinidase deficiency | 2023-06-06 | criteria provided, single submitter | clinical testing |